Results 31 to 40 of about 5,374,876 (288)

Health disparities in chronic liver disease

open access: yesHepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian   +3 more
wiley   +1 more source

Costos directos y aspectos clínicos de las reacciones adversas a medicamentos en pacientes hospitalizados en el servicio de medicina interna de una institución de tercer nivel de Bogotá.

open access: yesBiomédica: revista del Instituto Nacional de Salud, 2006
Introducción. Las reacciones adversas a medicamentos constituyen un problema clínico frecuente en el ámbito hospitalario y aumentan los costos de la atención en salud.
Gabriel Tribiño   +3 more
doaj   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Economic Analysis of Intravenous Iron in Patients with Iron Deficiency Anemia Due to Inflammatory Bowel Disease: Considerations for Clinicians [Letter]

open access: yesClinicoEconomics and Outcomes Research, 2022
Richard F Pollock,1 Anjan Dhar,2 Matthew Johnson3 1Health Economics and Outcomes Research, Covalence Research Ltd, London, UK; 2Department of Gastroenterology, County Durham & Darlington NHS Foundation Trust, Darlington, Co.
Pollock RF, Dhar A, Johnson M
doaj  

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

New Integrated Information System for Pusan National University Hospital [PDF]

open access: yesHealthcare Informatics Research, 2011
ObjectivesThis study presents the information system for Pusan National University Hospital (PNUH), evaluates its performance qualitatively, and conducts economic analysis.MethodsInformation system for PNUH was designed by component-based development and
Hyung Hoi Kim   +8 more
doaj   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Modbury Hospital Exterior photo

open access: yes, 1981
Black and white photo of the exterior of Modbury ...
Modbury Hospital
core   +1 more source

Estimate of production function in selected public hospitals of Isfahan University of Medical Sciences

open access: yesمدیریت اطلاعات سلامت, 2013
Introduction: Using economic principles and after that evaluating economical operation of hospitals cause the correction of procedures and continuation of activities and provide economic managing of hospital’s industry.
saeed karimi   +3 more
doaj  

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy